These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer? Thio CL J Hepatol; 2006 Jan; 44(1):1-3. PubMed ID: 16293338 [No Abstract] [Full Text] [Related]
3. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B]. DING JG; SUN QF; FU RQ; WU YH; HONG L Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209 [No Abstract] [Full Text] [Related]
4. Adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B. Mukherjee S N Engl J Med; 2003 Jun; 348(24):2468; author reply 2468. PubMed ID: 12802037 [No Abstract] [Full Text] [Related]
5. [Efficacy of adefovir treatment in the lamivudine-resistant chronic hepatitis B patients]. Chen CY; Tu XL; Cheng QH; Dai Y Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):942-3. PubMed ID: 21205485 [No Abstract] [Full Text] [Related]
6. [Effect of adefovir and lamivudine combination therapy on lamivudine resistance chronic hepatitis B patients for 48 weeks]. Xu QJ; Liang ZG; He ZK Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):540-1. PubMed ID: 20678449 [No Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000 [TBL] [Abstract][Full Text] [Related]
8. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954 [TBL] [Abstract][Full Text] [Related]
9. [Adefovir dipivoxil--a further step in the control of chronic viral hepatitis B. There is still a long way to go]. Husa P Vnitr Lek; 2004 Mar; 50(3):177-80. PubMed ID: 15125364 [No Abstract] [Full Text] [Related]
10. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Aloman C; Wands JR Hepatology; 2003 Dec; 38(6):1584-7. PubMed ID: 14655682 [No Abstract] [Full Text] [Related]
11. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399 [TBL] [Abstract][Full Text] [Related]
12. Adefovir for lamivudine resistant HBV: more than meets the eye. Di Marco V; Craxì A J Hepatol; 2007 Oct; 47(4):618-9; author reply 619-20. PubMed ID: 17697727 [No Abstract] [Full Text] [Related]
13. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. Yang Q; Gong ZJ; Hu DF Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686 [TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233 [TBL] [Abstract][Full Text] [Related]
15. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. Marcellin P; Asselah T J Hepatol; 2005 Dec; 43(6):920-3. PubMed ID: 16246449 [No Abstract] [Full Text] [Related]
16. [Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil]. Palumbo E Recenti Prog Med; 2007 Apr; 98(4):237-8. PubMed ID: 17547362 [TBL] [Abstract][Full Text] [Related]
17. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. Westland CE; Yang H; Delaney WE; Wulfsohn M; Lama N; Gibbs CS; Miller MD; Fry J; Brosgart CL; Schiff ER; Xiong S J Viral Hepat; 2005 Jan; 12(1):67-73. PubMed ID: 15655050 [TBL] [Abstract][Full Text] [Related]
18. Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. Chen Y; Ju T Int J Infect Dis; 2012 Mar; 16(3):e152-8. PubMed ID: 22226087 [TBL] [Abstract][Full Text] [Related]
19. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. van der Poorten D; Prakoso E; Khoo TL; Ngu MC; McCaughan GW; Strasser SI; Lee AU J Gastroenterol Hepatol; 2007 Sep; 22(9):1500-5. PubMed ID: 17683493 [TBL] [Abstract][Full Text] [Related]
20. [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. Jung HW; Choi MS; Kim KH; Park SH; Yeon KK; Lee JH; Koh KC; Paik SW; Yoo BC Korean J Hepatol; 2009 Mar; 15(1):52-8. PubMed ID: 19346785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]